eFFECTOR Therapeutics Statistics
Share Statistics
eFFECTOR Therapeutics has 4.7M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 4.7M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 91.62K, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 91.62K |
| Short % of Shares Out | n/a |
| Short % of Float | 2.17% |
| Short Ratio (days to cover) | 0.97 |
Valuation Ratios
The PE ratio is -0.71 and the forward
PE ratio is null.
eFFECTOR Therapeutics's PEG ratio is
-0.01.
| PE Ratio | -0.71 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -4.41 |
| P/FCF Ratio | -0.86 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for eFFECTOR Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.77,
with a Debt / Equity ratio of -3.55.
| Current Ratio | 0.77 |
| Quick Ratio | 0.77 |
| Debt / Equity | -3.55 |
| Debt / EBITDA | -0.61 |
| Debt / FCF | -0.69 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,557,928.57 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.43, so eFFECTOR Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.43 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 36.29 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -22.92M |
| Operating Income | -33.84M |
| Net Income | -35.81M |
| EBITDA | -33.73M |
| EBIT | -38.73M |
| Earnings Per Share (EPS) | -16.37 |
Full Income StatementBalance Sheet
The company has 14.88M in cash and 20.55M in
debt, giving a net cash position of -5.67M.
| Cash & Cash Equivalents | 14.88M |
| Total Debt | 20.55M |
| Net Cash | -5.67M |
| Retained Earnings | -179.38M |
| Total Assets | 27.13M |
| Working Capital | 681K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -29.55M
and capital expenditures -97K, giving a free cash flow of -29.65M.
| Operating Cash Flow | -29.55M |
| Capital Expenditures | -97K |
| Free Cash Flow | -29.65M |
| FCF Per Share | -13.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
